[Metabolic effects of various palliative drugs for coronary insufficiency].
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000378:metabolism; D003327:Coronary Disease / Q000188:drug therapy* / Q000378:metabolism; D004176:Dipyridamole / Q000494:pharmacology; D004285:Dogs; D004357:Drug Synergism; D005958:Glucosephosphates / Q000378:metabolism; D006321:Heart / Q000187:drug effects*; D006801:Humans; D009206:Myocardium / Q000378:metabolism*; D010101:Oxygen Consumption; D011299:Prenylamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D013565:Sympatholytics / Q000494:pharmacology* / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000494:pharmacology* / Q000627:therapeutic use; D014700:Verapamil / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D005958:Glucosephosphates; D013565:Sympatholytics; D014665:Vasodilator Agents; D004176:Dipyridamole; D011433:Propranolol; D014700:Verapamil; D011299:Prenylamine; D002118:Calcium
Effets metaboliques de quelques meicaments palliatifs de l'insuffisance coronarienne.